FDA's AI SaMD Lifecycle Guidance Meets a 1,451-Device Reality
What happened
IntuitionLabs summarized the FDA's current posture on AI and machine learning in medical devices, including the February 2026 lifecycle management guidance for AI/ML software as a medical device and its alignment with the Quality Management System Regulation. As of early 2026, the FDA's public list shows 1,451 AI-enabled medical devices authorized for marketing, with roughly 295 of those cleared in 2025 alone.
Why it matters for hospital/HealthTech buyers
The volume matters. When more than a thousand AI-enabled devices are on the market, hospital procurement can no longer treat "AI-enabled" as a special classification requiring one-off review. It becomes a standing capability that clinical, IT, and biomedical engineering teams have to evaluate in the ordinary course of business.
QMSR alignment adds another dimension. Lifecycle management guidance means the FDA is treating AI performance as something that must be monitored, documented, and updated over time, not certified once and forgotten. That shifts the cost of ownership for both hospitals and vendors, because model drift monitoring, revalidation, and change control now sit inside the regulated envelope.
"As of early 2026, the FDA's publicly updated list shows 1,451 AI-enabled medical devices authorized for marketing since 1995, with approximately 295 new authorizations in 2025 alone." — IntuitionLabs
Our take
The 295 authorizations in a single year tell you where the market is. The QMSR alignment tells you where it is going. Hospitals that still route every AI clearance through an ad-hoc committee are going to drown in the volume, and vendors that treated FDA authorization as a one-time milestone are going to get caught flat-footed the first time a hospital asks for post-market performance data. The winning pattern on both sides is the same: build repeatable, boring, documented processes for AI intake, monitoring, and change control, and treat them like any other quality system. Hospitals that operationalize this in 2026 will spend meaningfully less on their AI portfolio in 2027 than the ones still doing bespoke reviews.
Want the full report?
We'll take you straight to the source — one form, no drip campaigns.
Source: IntuitionLabs, recent. Quotes reproduced under fair use for commentary.
Answers
- What's the source of this analysis?
- Source: IntuitionLabs, recent. Quotes reproduced under fair use for commentary.
- Why does this matter?
- The FDA's February 2026 lifecycle management guidance for AI/ML software as a medical device now sits on top of a market with 1,451 authorized AI devices, 295 of them cleared in 2025 alone. QMSR alignment turns compliance into a continuous product commitment.
- What should I do next?
- Read the original source — Read the original at IntuitionLabs — or reply to the team at medoutbound to discuss how it applies to your buying committee.